|
Total n. of patients
|
174 (100)
|
|
Sex
| |
|
Male
|
80 (46)
|
|
Female
|
94 (54)
|
|
Median age (range)
|
62 years (28–79)
|
|
ECOG Performance Status
| |
|
0
|
106 (61)
|
|
1
|
52 (30)
|
|
2
|
16 (9)
|
|
Site of primary tumor
| |
|
Intrahepatic
|
86 (49)
|
|
Extrahepatic
|
37 (21)
|
|
Gallbladder
|
34 (20)
|
|
Ampullary
|
17 (10)
|
|
CA19.9 before second-line CT
| |
|
< Median value (157 U/ml)
|
71 (41)
|
|
≥ Median value (157 U/ml)
|
83 (48)
|
|
Data missing
|
20 (11)
|
|
Previous response to first-line CT
| |
|
Partial response
|
37 (21.3)
|
|
Stable disease
|
70 (40.3)
|
|
Progressive disease
|
67 (38.4)
|
|
Median PFS to first-line CT
|
5.8 months
|
|
Third-line CT received
|
74 (43)
|
|
Platinum plus or minus gemcitabine or fluoropyrimidine
|
24 (14)
|
|
Irinotecan plus or minus 5-fluorouracil or capecitabine
|
17 (10)
|
|
Monotherapy with 5-fluorouracil or capecitabine
|
10 (6)
|
|
Monotherapy with paclitaxel or docetaxel
|
7 (4)
|
|
Monotherapy with epirubicin
|
5 (3)
|
|
Other regimens
|
11 (6)
|
